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Depression and Panic in Patients with 
Borderline Personality Disorder 
Leon Grunhaus, Douglas King, John F. Greden, and Pam Flegel 
Introduction 
The borderline personality concept has evolved 
from a term used to describe a neurotic- 
psychotic borderland (Knight 1963), or an al- 
most but-not-quite schizophrenic process (Hock 
and Polatin 1949), to a more precise and op- 
erationally defined syndrome (American Psy- 
chiatric Association, 1980; Gunderson 1982). 
Affective changes are a major and consistent 
clinical feature in most descriptions of border- 
line personality disorders (BPD). Major de- 
pressive disorder (MDD) or other DSM-III Axis 
I diagnoses, including panic disorder, may be 
present in a significant number of BPD patients, 
perhaps in the majority (Carroll et al. 1980; 
Akiskal 1981; Stone 1981; Pope et al. 1983). 
Thus, the appropriate treatment of patients with 
combined Axis I (MDD) and Axis II (BPD) 
pathology would require psychotropic medica- 
tions. Pope et al. (1983) reported that BPD pa- 
tients who had associated MDD and were treated 
with psychotropic medications had better out- 
come measures when interviewed 4-7 years af- 
ter the index hospitalization. 
Agoraphobia and panic disorder also have 
been reported as being occasionally associated 
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with BPD (Akiskal 1981; Stone 1981; Pope et 
al. 1983); this is somewhat surprising, because 
early and current descriptions of BPD (Hock and 
Polatin 1949; Grinker et al. 1968; Kemberg 1975) 
repeatedly refer to pervasive anxiety and pho- 
bias as consistent features in BPD. One possible 
explanation for this relative low frequency of 
the reported association of BPD with anxiety 
disorders may be due to the design of the rating 
instruments and diagnostic systems used for the 
study of BPD. Current rating instruments, such 
as the Diagnostic Interview for Borderline (DIB) 
(Gunderson et al. 1981) or the Borderline Per- 
sonality Inventory (BPI) (Perry and Klerman 
1980), emphasize anxiety symptoms only 
vaguely. Those diagnostic systems with oper- 
ational definitions of psychiatric entities, such 
as the DSM-m (American Psychiatric Associ- 
ation 1980) or the Research Diagnostic Criteria 
(RDC) (Spitzer et al. 1978), exclude anxiety 
diagnosis in the presence of significant dys- 
phoria. 
The diagnosis of panic disorder in patients 
with borderline disorder, either with or without 
MDD, may be of importance. BPD patients with 
associated panic may have a drug-responsive 
syndrome, thus increasing the possibilities of a 
favorable outcome (Akiskal 1981; Stone 1981). 
BPD patients with associated major depressive 
disorder and panic disorder may have distinctive 
clinical features, poorer treatment response, and 
increased chronicity of the illness (Leckman et 
al. 1983; Van Valkenburg et al. 1984). 
mired). 
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disorder in BPD patients, we analyzed the clin- 
ical features of 28 patients meeting the diagnosis 
of B PD, following Gunderson and Singer's (1975) 
criteria. Sixty-eight percent of the patients met 
both diagnoses of BPD and MDD, and 37% of 
these also had panic disorder. We found no pa- 
tients with BPD and panic disorder in the ab- 
sence of MDD. 
Me t hods  
The Clinical Studies Unit of the University of 
Michigan Hospitals is a research and treatment 
facility specializing in affective disorders. Pa- 
tients routinely are evaluated with a diagnostic 
procedure consisting of: (1) a 14-day drug with- 
drawal period; (2) several independent clinical 
evaluations of psychiatric and medical com- 
plaints; (3) a structured diagnostic interview-- 
Schedule for Affective Disorders and Schizo- 
phrenia; (4) a review of all past medical records 
to confirm longitudinal course whenever pos- 
sible; and (5) a comprehensive physical exam- 
ination and thorough laboratory screening to rule 
out serious medical illnesses. After completion 
of the baseline evaluation and research proce- 
dures, staff members meet in a weekly diag- 
nostic conference to review data, integrate in- 
formation, and compile diagnoses based on the 
Research Diagnostic Criteria (RDC) (Spitzer et 
al. 1978). Information on the patients included 
in this study was accumulated on an ongoing 
basis throughout the years 1976--1980. 
Subjects 
Patients had to meet the following inclusion cri- 
teria: (1) a diagnosis of borderline personality 
disorder following Gunderson and Singer's 
guidelines (Gunderson and Singer 1975), (2) a 
complete SADS interview with adequate ratings 
for panic attacks in the current episode of ill- 
ness, and (3) the 17-item Hamilton Rating Scale 
for Depression (HRSD). The SADS interviews 
were analyzed for the presence of recurrent panic 
attacks. It is important to note that we diagnosed 
panic disorder even in the presence of MDD. 
Twenty-eight patients met our inclusion criteria 
and were grouped according to diagnosis: Group 
1 (n = 9), those with BPD alone; Group 2 
(n = 12), those with BPD and MDD and no 
panic disorder; and Group 3 (n = 7), those with 
BPD, MDD, and panic disorder diagnosis. We 
then analyzed the HRSD ratings (total and items) 
and age distribution for the three groups of pa- 
tients using a one-way analysis of variance. Cat- 
egorical data were analyzed using a chi-square 
test. 
Resul ts  
The sample consisted of 5 males and 23 females. 
The sex distribution was similar in the three 
groups of patients (×2 = 0.18, df = 2, NS). 
The mean age was 28.57 --- 8.6 years; no sig- 
nificant age differences between the groups were 
identified (F = 1.57, NS). Of the 28 patients, 
19 (68%) met the diagnosis of MDD; of these, 
7 (25% of the total sample and 37% of the pa- 
tients with MDD) had simultaneous MDD and 
panic disorder. 
Table 1 presents the ANOVA results for the 
HRSD ratings. As mentioned previously, Group 
1 represents those patients having just BPD, 
Group 2 those with MDD and BPD, and Group 
3 those with BPD, MDD, and panic disorder. 
Significant differences between the groups oc- 
curred for the HRSD items of suicide (p < 0.05), 
somatic anxiety (p < 0.01), and hypochon- 
driasis (p < 0.01); a significant trend was noted 
for the item of guilt. Although Group 2 had 
higher ratings for hypochondriasis, Group 3 rated 
highest for somatic anxiety, suicide, and guilt. 
When contrasts among the groups were made, 
the major significant differences occurred be- 
tween those who have the three joint diagnoses 
and BPD alone (total HRSD, guilt, somatic anx- 
iety, and suicidality). 
Discuss ion  
In this small sample of BPD patients, 68% had 
an Axis I diagnosis of MDD, and interestingly, 
37% of these BPD and MDD patients also met 
our modified DSM-III criteria for panic disor- 
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Table 1. T w o - W a y  A N O V A  of Significant HRSD Ratings (Total and Items) in Patients with 
BPD Alone ( G r o u p  1), MDD and BPD ( G r o u p  2),  and MDD, BPD, and P D  ( G r o u p  3) 
HRSD Mean _+ SD F Contrasts 
Total HRSD 18.88 -+ 6.54 1.922 us  
Group 1 15.55 - 6.87 (3 vs 2) 0.09 us 
Group 2 20.18 - 6.75 (3 vs 1) 3.06" 
Group 3 21.14 _ 4.60 (2 vs 1) 2.64 us  
( 3 + 2  vs 1) 3.8ff' 
Guilt 1.25 -+ 0.94 2.96 a 
Group 1 0.77 -+ 0.83 (3 vs 2) 1.88 US 
Group 2 1.27 -+ 0.64 (3 vs 1) 5.92 b 
Group 3 1.85 -+ 1.21 (2 vs 1) 1.56 us  
( 3 + 2  vs 1) 3.90 b 
Suicide 1.79 -+ 1.09 3.62 b 
Group 1 1.33 - 1.00 (3 vs 2) 4.35 ° 
Group 2 1.63 -+ 1.12 (3 vs 1) 6.77 c 
Group 3 2.64 _ 0.74 (2 vs 1) 0.45 us 
( 3 + 2  vs 1) 2.56 us 
Work and interests 2.29 -+ 1.04 1.94 Ns 
Group 1 1.77 -- 1.30 (3 vs 2) 0.28 us 
Group 2 2.45 _+ 0.68 (3 vs 1) 3.42 a 
Group 3 2.71 -+ 0.99 (2 vs l)  2.24 us 
( 3 + 2  vs 1) 3.42 a 
Somatic anxiety 1.12 -+ 0.95 5.46 c 
Group 1 0.55 - 0.528 (3 vs 2) 4.40 b 
Group 2 1.09 __ 0.949 (3 vs 1) 10.9(Y 
Group 3 1.92 -4- 0.930 (2 vs 1) 2.08 us  
( 3 + 2  vs 1) 5 . 7 ~  
HYlxx:hondriasis 0.48 -4- 0.75 7.65 c 
Group 1 0 (3 vs 2) 2.23 us  
Group 2 0.90 + 0.94 (3 vs 1) 1.63 us  
Group 3 0.42 .4- 0.53 (2 vs 1) 9.24 b 
( 3 + 2  vs 1) 6.70 ~ 
ap < 0.1. 
~v < 0.05. 
Cp < 0.01. 
der, thus having two associated Axis I diag- 
noses. None of the patients had panic disorder 
in the absence of MDD. The patients with BPD, 
MDD, and panic had higher HRSD ratings than 
patients with BPD alone. This in itself is not 
surprising, because the HRSD is assessing af- 
fective changes in this population. However, 
particular items of the HRSD scale were sig- 
nificantly different between the groups, whereas 
the depressed mood rating was not. Overall pa- 
tients with BPD, MDD, and panic seemed more 
guilty, suicidal, and somatically anxious. These 
findings are applicable to a population of hos- 
pitalized BPD patients. It is unclear whether or 
not they can be generalized to all BPD patients. 
The heuristic value of this report lies in the 
identification of a subgroup of BPD patients that 
may be pharmacologically treatable. 
Recent reports suggest that patients who have 
joint MDD and panic disorder might differ from 
those with pure MDD on several parameters. 
First, with regard to clinical features (Grunhaus 
et al. 1984; Van Valkenburg et al. 1984), it has 
been noted that patients with joint MDD and 
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panic have lower ratings for guilt and depression 
and higher ratings for hypochondriacal features, 
somatic and psychological anxiety, and deper- 
sonalization and derealization. Second, the 
treatment response, the psychosocial outcome, 
and the chronicity of the illness (Van Valken- 
burg et al. 1984) seem to be worse in patients 
with both conditions. Third, Leckman et al. 
(1983) have shown that patients with joint MDD 
and panic have a higher incidence of family 
pathology, whether anxiety, depression, or al- 
coholism, than patients with MDD or panic alone. 
Fourth, the biological features (Grunhaus et al. 
1984) are affected in that the sensitivity and 
specificity of the Dexamethasone Suppression 
Test seems to be lower in patients with MDD 
and panic than in a matched group of patients 
with MDD alone; also, the REM latency of pa- 
tients with the joint syndrome approaches nor- 
mal values and does not show the reported low 
REM latency of MDD patients. 
Pope et al. (1983) stressed the importance of 
adequate drug treatment of those BPD patients 
with MDD. He found that BPD patients with 
MDD who were pharmacologically treated had 
a tendency for better long-term outcome and 
global assessments and more successful occu- 
pational status. Also, 6 of 14 patients with BPD 
and MDD at baseline had no identifiable bor- 
derline features during the follow-up interviews, 
which occurred 4-7 years after the index hos- 
pitalization, suggesting that the initial person- 
ality pathology was secondary to the affective 
process. The authors did not report whether or 
not MDD was associated with panic disorder. 
The rating instrument (the DIB) and diagnostic 
classification (the DSM-III) used by these au- 
thors did not allow this distinction. However, 
two of their patients met BPD and panic diag- 
noses. 
The presence of affective and panic pathol- 
ogy in BPD patients seems to confer some par- 
ticular characteristics on the clinical picture. This 
may also be true with regard to the treatment 
response. The finding (Pope et al. 1983) that 
some patients may not reveal BPD pathology 
after successful treatment for their MDD is very 
intriguing and may mean that some of the more 
classical borderline features, such as acting-out 
behavior, severe mood swings, drug abuse, etc., 
are in fact state, and not trait, related. The need 
for a pharmacological trial of antidepressants, 
particularly monoamine oxidase inhibitors, in 
these patients is stressed by the favorable out- 
come described for patients with atypical 
depression and panic attacks when treated with 
phenelzine (Liebowitz et al. 1984). Both affec- 
tive and panic pathology may be responsible for 
these mood-related features of borderline pa- 
tients and should be addressed when performing 
diagnostic assessments or treatment recommen- 
dations for these patients. 
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Resting Metabolic Rate is Reduced in Patients 
Treated with Antidepressants 
Madelyn H. Fernstrom, Leonard H. Epstein, Duane G. Spiker, and 
David J. Kupfer 
Introduction 
Eating disturbances, most notably a decrease in 
appetite and weight loss, are associated with 
major depression (Robinson et al. 1975; Paykel 
1977; Mezzich and Raab 1980). During anti- 
depressant treatment, many symptoms of 
depression disappear (including appetite loss), 
and patients begin to gain weight. Several stud- 
ies have shown that certain antidepressants, par- 
ticularly tricyclic compounds, are associated with 
excessive weight gain (Paykel et al 1974; Kupfer 
et al. 1979; Berken et al. 1984). However, few 
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comprehensive data exist that focus on factors 
influencing weight change upon recovery from 
a depressive episode. 
Weight fluctuations reflect both caloric intake 
and caloric expenditure. Thus, weight gain is 
due to positive energy balance, which may be 
explained by an increase in total calories con- 
sumed and/or a reduction in calories used by 
the body. Resting metabolic rate (RMR), which 
reflects the number of calories utilized by an 
individual in a resting state, represents at least 
70% of the total caloric utilization by an indi- 
vidual (Garrow 1978); RMR probably accounts 
for an even greater proportion of calories in 
hospitalized patients due to their greater inac- 
tivity. Therefore, if a reduction in metabolic rate 
occurs, an individual would gain weight without 
increasing caloric intake. Thus, we wanted to 
determine whether or not alterations in resting 
metabolic rate might occur in drug-treated de- 
pressed patients; such changes might ultimately 
contribute to potential weight changes. 
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